Please assess the completion status of the following clinical trial:

Trial Title: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Group 1: Voluntary HIV positive subjects~Inclusion Criteria:~* Adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment)~* \> 350 CD4/mm3 (with half of them a nadir \< 200 CD4/mm3) and a viral load \< 50 copies/mL for at least 6 months.~* Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.~Exclusion Criteria:~* Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive.~* Administration of immunoglobulins \< 3 months or any vaccine \<1 month.~* Pregnancy ongoing or planned during the study.~* Coinfection with HCV virus untreated.~* HBs Ag positive.~* Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance.~* Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses ≥ 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months.~* History of thymic dysfunction (including thymoma and thymectomy).~* For HIV + subjects: ART Celsentri or by other anti-CCR5.~Group 2: HIV negative subjects~Inclusion Criteria:~HIV and HCV negatives~Exclusion Criteria:~* Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive.~* Administration of immunoglobulins \< 3 months or any vaccine \<1 month.~* Other vaccinations should be deferred beyond M3.~* Pregnancy ongoing or planned during the study.~* Coinfection with HCV virus untreated.~* HBs Ag positive.~* Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance.~* Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses ≥ 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months.~* History of thymic dysfunction (including thymoma and thymectomy).~* For HIV + subjects: ART Celsentri or by other anti-CCR5, coinfection with HCV virus untreated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Voluntary HIV positive subjects (Type: ACTIVE_COMPARATOR): 40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), \> 350 CD4/mm3 (with half of them a nadir \< 200 CD4/mm3) and a viral load \< 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
- HIV negative subjects (Type: OTHER): Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year

Based on this trial design, predict the completion outcome and termination type (if applicable).